Jemperli

Quick orientation

Jemperli (dostarlimab-gxly) is a humanised anti-PD-1 monoclonal antibody developed by GSK. The US Food and Drug Administration first granted accelerated approval to Jemperli in April 2021 for adults with mismatch-repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or after platinum-containing chemotherapy, with subsequent expanded approval in dMMR solid tumours and, in 2023, first-line use in combination with carboplatin and paclitaxel for primary advanced or recurrent dMMR endometrial cancer. Dosing is intravenous every three weeks for four cycles, then every six weeks as monotherapy. Treatment is administered in an oncology infusion centre under medical oncology or gynaecologic oncology supervision, with immune-related adverse-event surveillance throughout.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How Reserve Meds coordinates Jemperli

1. Patient or treating physician submits an intake at the patient portal.
2. Reserve Meds clinical team verifies appropriateness for the patient and destination country.
3. Treating physician issues prescription and clinical justification.
4. Country-specific named-patient documentation is prepared.
5. Jemperli is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.

Access by country

Reserve Meds publishes a detailed country access guide for Jemperli in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.

Start a request for Jemperli

Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.

Start your case Or message us on WhatsApp